These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34767925)

  • 1. Patient-derived xenograft models of neuroendocrine prostate cancer.
    Shi M; Wang Y; Lin D; Wang Y
    Cancer Lett; 2022 Jan; 525():160-169. PubMed ID: 34767925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.
    Philp LK
    Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
    Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
    Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
    Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
    Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series.
    Anselmino N; Labanca E; Shepherd PDA; Dong J; Yang J; Song X; Nandakumar S; Kundra R; Lee C; Schultz N; Zhang J; Araujo JC; Aparicio AM; Subudhi SK; Corn PG; Pisters LL; Ward JF; Davis JW; Vazquez ES; Gueron G; Logothetis CJ; Futreal A; Troncoso P; Chen Y; Navone NM
    Clin Cancer Res; 2024 May; 30(10):2272-2285. PubMed ID: 38488813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LIN28B promotes the development of neuroendocrine prostate cancer.
    Lovnicki J; Gan Y; Feng T; Li Y; Xie N; Ho CH; Lee AR; Chen X; Nappi L; Han B; Fazli L; Huang J; Gleave ME; Dong X
    J Clin Invest; 2020 Oct; 130(10):5338-5348. PubMed ID: 32634132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
    Beltran H; Rickman DS; Park K; Chae SS; Sboner A; MacDonald TY; Wang Y; Sheikh KL; Terry S; Tagawa ST; Dhir R; Nelson JB; de la Taille A; Allory Y; Gerstein MB; Perner S; Pienta KJ; Chinnaiyan AM; Wang Y; Collins CC; Gleave ME; Demichelis F; Nanus DM; Rubin MA
    Cancer Discov; 2011 Nov; 1(6):487-95. PubMed ID: 22389870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression.
    Lee AR; Li Y; Xie N; Gleave ME; Cox ME; Collins CC; Dong X
    Oncotarget; 2017 Apr; 8(17):27966-27975. PubMed ID: 28427194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.
    Beshiri ML; Tice CM; Tran C; Nguyen HM; Sowalsky AG; Agarwal S; Jansson KH; Yang Q; McGowen KM; Yin J; Alilin AN; Karzai FH; Dahut WL; Corey E; Kelly K
    Clin Cancer Res; 2018 Sep; 24(17):4332-4345. PubMed ID: 29748182
    [No Abstract]   [Full Text] [Related]  

  • 10. Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development.
    Ci X; Hao J; Dong X; Xue H; Wu R; Choi SYC; Haegert AM; Collins CC; Liu X; Lin D; Wang Y
    Cells; 2020 Jun; 9(6):. PubMed ID: 32512818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Novel Models of Aggressive Variants of Castration-resistant Prostate Cancer.
    Bigot L; Sabio J; Poiraudeau L; Annereau M; Menssouri N; Helissey C; Déas O; Aglave M; Ibrahim T; Pobel C; Nobre C; Nicotra C; Ngo-Camus M; Lacroix L; Rouleau E; Tselikas L; Judde JG; Chauchereau A; Bernard-Tessier A; Patrikidou A; Naoun N; Flippot R; Colomba E; Fuerea A; Albiges L; Lavaud P; Massard C; Friboulet L; Fizazi K; Besse B; Scoazec JY; Loriot Y
    Eur Urol Oncol; 2024 Jun; 7(3):527-536. PubMed ID: 38433714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.
    Palanisamy N; Yang J; Shepherd PDA; Li-Ning-Tapia EM; Labanca E; Manyam GC; Ravoori MK; Kundra V; Araujo JC; Efstathiou E; Pisters LL; Wan X; Wang X; Vazquez ES; Aparicio AM; Carskadon SL; Tomlins SA; Kunju LP; Chinnaiyan AM; Broom BM; Logothetis CJ; Troncoso P; Navone NM
    Clin Cancer Res; 2020 Sep; 26(18):4933-4946. PubMed ID: 32576626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer.
    Sulsenti R; Scialpi GB; Frossi B; Botti L; Ferri R; Tripodi I; Piva A; Sangaletti S; Pernici D; Cancila V; Romeo F; Chiodoni C; Lecis D; Bianchi F; Fischetti I; Enriquez C; Crivelli F; Bregni M; Renne G; Pece S; Tripodo C; Pucillo CE; Colombo MP; Jachetti E
    Cancer Immunol Res; 2024 Sep; 12(9):1147-1169. PubMed ID: 38869181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology.
    Risbridger GP; Clark AK; Porter LH; Toivanen R; Bakshi A; Lister NL; Pook D; Pezaro CJ; Sandhu S; Keerthikumar S; Quezada Urban R; Papargiris M; Kraska J; Madsen HB; Wang H; Richards MG; Niranjan B; O'Dea S; Teng L; Wheelahan W; Li Z; Choo N; Ouyang JF; Thorne H; Devereux L; Hicks RJ; Sengupta S; Harewood L; Iddawala M; Azad AA; Goad J; Grummet J; Kourambas J; Kwan EM; Moon D; Murphy DG; Pedersen J; Clouston D; Norden S; Ryan A; Furic L; Goode DL; Frydenberg M; Lawrence MG; Taylor RA
    Nat Commun; 2021 Aug; 12(1):5049. PubMed ID: 34413304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.
    Porter LH; Lawrence MG; Wang H; Clark AK; Bakshi A; Obinata D; Goode D; Papargiris M; Mural ; Clouston D; Ryan A; Norden S; Corey E; Nelson PS; Isaacs JT; Grummet J; Kourambas J; Sandhu S; Murphy DG; Pook D; Frydenberg M; Taylor RA; Risbridger GP
    Prostate; 2019 Aug; 79(11):1326-1337. PubMed ID: 31212368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4.
    Coleman DJ; Sampson DA; Sehrawat A; Kumaraswamy A; Sun D; Wang Y; Schwartzman J; Urrutia J; Lee AR; Coleman IM; Nelson PS; Dong X; Morrissey C; Corey E; Xia Z; Yates JA; Alumkal JJ
    Neoplasia; 2020 Jun; 22(6):253-262. PubMed ID: 32403054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
    Li Y; Xie N; Chen R; Lee AR; Lovnicki J; Morrison EA; Fazli L; Zhang Q; Musselman CA; Wang Y; Huang J; Gleave ME; Collins C; Dong X
    Eur Urol; 2019 Aug; 76(2):157-166. PubMed ID: 30910347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
    Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
    Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance.
    Lam HM; Nguyen HM; Corey E
    Methods Mol Biol; 2018; 1786():1-27. PubMed ID: 29786784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ONECUT2 is a driver of neuroendocrine prostate cancer.
    Guo H; Ci X; Ahmed M; Hua JT; Soares F; Lin D; Puca L; Vosoughi A; Xue H; Li E; Su P; Chen S; Nguyen T; Liang Y; Zhang Y; Xu X; Xu J; Sheahan AV; Ba-Alawi W; Zhang S; Mahamud O; Vellanki RN; Gleave M; Bristow RG; Haibe-Kains B; Poirier JT; Rudin CM; Tsao MS; Wouters BG; Fazli L; Feng FY; Ellis L; van der Kwast T; Berlin A; Koritzinsky M; Boutros PC; Zoubeidi A; Beltran H; Wang Y; He HH
    Nat Commun; 2019 Jan; 10(1):278. PubMed ID: 30655535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.